Bay Area firms lead revolution in cancer care
Genentech has developed three of the most promising cancer drugs — Herceptin, Rituxan for non-Hodgkin’s lymphoma and Avastin for non-small-cell lung cancer and colorectal cancer. Another key cancer drug is Novartis’ Gleevec for chronic myeloid leukemia.
This entry was posted on Friday, June 29th, 2007 at 8:51 am and is filed under Research, Non-Small-Cell. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.